Prasugrel or clopidogrel in non-st-elevation acute coronary syndrome with CYP2C19 genetic variants undergoing percutaneous coronary intervention

25 August 2018 (00:00 - 00:00)

Organised by:

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Soojin Kim

Busan (Korea (Republic of))

5 More presentations in this session

Presentation thumbnail

HDL-cholesterol dysfunction and inflammation in patients with genotypes associated with different responses to dalcetrapib

Doctor A. Franci (Sao Paulo, BR)

Abstract Slides

Presentation thumbnail

Association of CYP2C19*2 and PEAR1 gene variant with platelet reactivity and clinical outcomes in patients undergoing stenting and treated with aspirin and clopidogrel

Doctor K. Xu (Shanghai, CN)

Abstract Slides

Presentation thumbnail

CYP2C19 genotyping as complementary tool for guidance of early de-escalation of antiplatelet treatment in acute coronary syndrome patients

Doctor L. Gross (Munich, DE)

Abstract Slides

Presentation thumbnail

Comparison of three different platelet function tests in patients on P2Y12 inhibitors in correlation to genetic background.

Mrs R. Olie (Maastricht, NL)

Presentation thumbnail

Genetic influence on warfarin dose determination

Doctor J. Li (Busan, KR)

Abstract Slides

Access the full session

Session thumbnail

Poster Session 6 - Pharmacogenetics - New sights on the horizon

The Event

ESC Congress 2018

25 August - 29 August 2018

You may be interested in

Congress Presentation

State-of-the-art lecture on pharmacotherapy for acute coronary syndromes

Webinar

Aspirin treatment for mitigating thrombotic risk across the cardiovascular risk continuum

Congress Session

State-of-the-art antithrombotic treatment in acute coronary syndromes: a paradigm shift?

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources